Investigational treatment strategies in glioblastoma: progress made and barriers to success

References

• Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022 Oct 5;24(Supplement_5):v1–95. doi: 10.1093/neuonc/noac202
   PubMedGoogle Scholar
• Grech N, Dalli T, Mizzi S, et al. Rising incidence of glioblastoma multiforme in a well-defined population. Cureus. 2020 May 19 [cited 2023 Jul 31]; Available from: https://www.cureus.com/articles/31024-rising-incidence-of-glioblastoma-multiforme-in-a-well-defined-population
   Google Scholar
• Lin D, Wang M, Chen Y, et al. Trends in intracranial glioma incidence and mortality in the United States, 1975-2018. Front Oncol. 2021 Nov 1;11:748061. doi: 10.3389/fonc.2021.748061
   PubMed Web of Science ®Google Scholar
• Stupp R, Weller M, Belanger K, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi: 10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep;48(14):2192–2202. doi: 10.1016/j.ejca.2012.04.011
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA. 2017 Dec 19;318(23):2306. doi: 10.1001/jama.2017.18718
   PubMed Web of Science ®Google Scholar
• Lassman AB, Joanta-Gomez AE, Pan PC, et al. Current usage of tumor treating fields for glioblastoma. Neuro-Oncol Adv. 2020 Jan 1;2(1):vdaa069. doi: 10.1093/noajnl/vdaa069
   PubMedGoogle Scholar
• Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980 Dec 4;303(23):1323–1329. doi: 10.1056/NEJM198012043032303
   PubMed Web of Science ®Google Scholar
• Yoshida J, Shibuya N, Kobayashi T, et al. Sensitivity to 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) of glioma cells in vivo and in vitro. Cancer. 1982 Aug 1;50(3):410–418. doi: 10.1002/1097-0142(19820801)50:3<410:AID-CNCR2820500305>3.0.CO;2-3
   PubMed Web of Science ®Google Scholar
• Wolff JEA, Trilling T, Mölenkamp G, et al. Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999 Aug 6;125(8–9):481–486. doi: 10.1007/s004320050305
   PubMed Web of Science ®Google Scholar
• Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet. 1995 Apr;345(8956):1008–1012. doi: 10.1016/S0140-6736(95)90755-6
   PubMed Web of Science ®Google Scholar
• Brem H, Ewend MG, Piantadosi S, et al. The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: phase I trial. J Neurooncol. 1995 Nov;26(2):111–123. doi: 10.1007/BF01060217
   PubMed Web of Science ®Google Scholar
• Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine(BCNU) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79–88. doi: 10.1093/neuonc/5.2.79
   PubMed Web of Science ®Google Scholar
• Barbarite E, Sick JT, Berchmans E, et al. The role of brachytherapy in the treatment of glioblastoma multiforme. Neurosurg Rev. 2017 Apr;40(2):195–211. doi: 10.1007/s10143-016-0727-6
   PubMed Web of Science ®Google Scholar
• Godard S, Getz G, Delorenzi M, et al. Classification of human astrocytic gliomas on the basis of gene expression: a Correlated group of Genes with angiogenic activity emerges as a strong predictor of Subtypes1,2. Canc resea. 2003 Oct;63(20):6613–25.
   PubMed Web of Science ®Google Scholar
• Lamszus K, Ulbricht U, Matschke J, et al. Levels of soluble vascular endothelial growth factor (VEGF) receptor 1 in Astrocytic tumors and its relation to malignancy, Vascularity, and VEGF-A. 2003 Apr;9(4): 1399–405.
   Google Scholar
• Jain HV, Nör JE, Jackson TL. Modeling the VEGF–Bcl-2–CXCL8 pathway in intratumoral agiogenesis. Bull Math Biol. 2008 Jan;70(1):89–117. doi: 10.1007/s11538-007-9242-9
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20;370(8):699–708. doi: 10.1056/NEJMoa1308573
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Desjardins A, Herndon JE, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007 Oct 20;25(30):4722–4729. doi: 10.1200/JCO.2007.12.2440
   PubMed Web of Science ®Google Scholar
• Chauffert B, Feuvret L, Bonnetain F, et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. Ann Oncol. 2014 Jul;25(7):1442–1447. doi: 10.1093/annonc/mdu148
   PubMed Web of Science ®Google Scholar
• Balana C, De Las Penas R, Sepúlveda JM, et al. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol. 2016 May;127(3):569–579. doi: 10.1007/s11060-016-2065-5
   PubMed Web of Science ®Google Scholar
• Wick W, Gorlia T, Bendszus M, et al. Lomustine and Bevacizumab in progressive glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954–1963. doi: 10.1056/NEJMoa1707358
   PubMed Web of Science ®Google Scholar
• Patel KS, Everson RG, Yao J, et al. Diffusion Magnetic Resonance Imaging Phenotypes Predict overall survival benefit from Bevacizumab or surgery in recurrent glioblastoma with large tumor burden. Neurosurgery. 2020 Nov;87(5):931–938. doi: 10.1093/neuros/nyaa135
   PubMed Web of Science ®Google Scholar
• De Groot JF, Fuller G, Kumar AJ, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol. 2010 Mar 1;12(3):233–242. doi: 10.1093/neuonc/nop027
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013 Jun 10;31(17):2205–2218. doi: 10.1200/JCO.2012.46.3653
   PubMed Web of Science ®Google Scholar
• Vredenburgh JJ, Cloughesy T, Samant M, et al. Corticosteroid use in patients with glioblastoma at first or second relapse treated with Bevacizumab in the BRAIN study. Oncology. 2010 Dec 1;15(12):1329–1334. doi: 10.1634/theoncologist.2010-0105
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with Metastatic Melanoma. N Engl J Med. 2010 Aug 19;363(8):711–723. doi: 10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 Mar 21;380(12):1116–1127. doi: 10.1056/NEJMoa1816714
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in advanced Nonsquamous non–small-Cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627–1639. doi: 10.1056/NEJMoa1507643
   PubMed Web of Science ®Google Scholar
• Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non–small-Cell lung cancer. N Engl J Med. 2015 May 21;372(21):2018–2028. doi: 10.1056/NEJMoa1501824
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 Jul 2;373(1):23–34. doi: 10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Hendriks LEL, Henon C, Auclin E, et al. Outcome of patients with non–small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol. 2019 Jul;14(7):1244–1254. doi: 10.1016/j.jtho.2019.02.009
   PubMed Web of Science ®Google Scholar
• Crinò L, Bronte G, Bidoli P, et al. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019 Mar;129:35–40.
   PubMed Web of Science ®Google Scholar
• Tringale KR, Reiner AS, Sehgal RR, et al. Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure. CNS Oncol. 2023 Mar 1;12(1):CNS93. doi: 10.2217/cns-2022-0014
   PubMedGoogle Scholar
• Reardon DA, Brandes AA, Omuro A, et al. Effect of nivolumab vs Bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020 Jul 1;6(7):1003. doi: 10.1001/jamaoncol.2020.1024
   PubMed Web of Science ®Google Scholar
• Omuro A, Brandes AA, Carpentier AF, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 2023 Jan 5;25(1):123–134. doi: 10.1093/neuonc/noac099
   PubMed Web of Science ®Google Scholar
• Lim M, Weller M, Idbaih A, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022 Nov 2;24(11):1935–1949. doi: 10.1093/neuonc/noac116
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen AX, Gartrell RD, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nat Med. 2019 Mar;25(3):462–469. doi: 10.1038/s41591-019-0349-y
   PubMed Web of Science ®Google Scholar
• Almairac F, Turchi L, Sakakini N, et al. ERK-Mediated loss of miR-199a-3p and induction of EGR1 act as a “toggle switch” of GBM cell dedifferentiation into NANOG- and OCT4-positive cells. Cancer Res. 2020 Aug 15;80(16):3236–3250. doi: 10.1158/0008-5472.CAN-19-0855
   PubMed Web of Science ®Google Scholar
• Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010 Nov;12(11):1113–1125. doi: 10.1093/neuonc/noq082
   PubMed Web of Science ®Google Scholar
• Venkataramani V, Tanev DI, Strahle C, et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature. 2019 Sep 26;573(7775):532–538. doi: 10.1038/s41586-019-1564-x
   PubMed Web of Science ®Google Scholar
• Venkatesh HS, Tam LT, Woo PJ, et al. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 2017 Sep;549(7673):533–537. doi: 10.1038/nature24014
   PubMed Web of Science ®Google Scholar
• Venkatesh HS, Morishita W, Geraghty AC, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019 Sep 26;573(7775):539–545. doi: 10.1038/s41586-019-1563-y
   PubMed Web of Science ®Google Scholar
• Cassidy JW, Caldas C, Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 2015 Aug 1;75(15):2963–2968. doi: 10.1158/0008-5472.CAN-15-0727
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JE, Kahng JY, et al. Human glioblastoma arises from subventricular zone cells with low-level driver mutations. Nature. 2018 Aug;560(7717):243–247. doi: 10.1038/s41586-018-0389-3
   PubMed Web of Science ®Google Scholar
• Chow DS, Horenstein CI, Canoll P, et al. Glioblastoma induces vascular dysregulation in nonenhancing peritumoral regions in humans. Am J Roentgenol. 2016 May;206(5):1073–1081. doi: 10.2214/AJR.15.14529
   PubMed Web of Science ®Google Scholar
• Montgomery MK, Kim SH, Dovas A, et al. Glioma-induced alterations in neuronal activity and neurovascular coupling during disease progression. Cell Rep. 2020 Apr;31(2):107500. doi: 10.1016/j.celrep.2020.03.064
   PubMed Web of Science ®Google Scholar
• Tesileanu CMS, Dirven L, Wijnenga MMJ, et al. Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro Oncol. 2020 Apr 15;22(4):515–523. doi: 10.1093/neuonc/noz200
   PubMed Web of Science ®Google Scholar
• Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol (Berl). 2010 Dec;120(6):707–718. doi: 10.1007/s00401-010-0781-z
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An Integrated genomic Analysis of human glioblastoma multiforme. Science. 2008 Sep 26;321(5897):1807–1812. doi: 10.1126/science.1164382
   PubMed Web of Science ®Google Scholar
• Bagley SJ, Kothari S, Rahman R, et al. Glioblastoma clinical trials: Current landscape and opportunities for improvement. Clin Cancer Res. 2022 Feb 15;28(4):594–602. doi: 10.1158/1078-0432.CCR-21-2750
   PubMed Web of Science ®Google Scholar
• June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018 Jul 5;379(1):64–73. doi: 10.1056/NEJMra1706169
   PubMed Web of Science ®Google Scholar
• Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 Feb;378(5):439–448. doi: 10.1056/NEJMoa1709866
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell Lymphoma. N Engl J Med. 2017 Dec 28;377(26):2531–2544. doi: 10.1056/NEJMoa1707447
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015 Apr 3;348(6230):69–74. doi: 10.1126/science.aaa4971
   PubMed Web of Science ®Google Scholar
• Li Y, Yang X, Wu Y, et al. B7-H3 promotes gastric cancer cell migration and invasion. Oncotarget. 2017 Sep 22;8(42):71725–71735. doi: 10.18632/oncotarget.17847
   PubMedGoogle Scholar
• Brown CE, Aguilar B, Starr R, et al. Optimization of IL13Rα2-targeted chimeric antigen receptor T cells for improved anti-tumor efficacy against glioblastoma. Mol Ther. 2018 Jan;26(1):31–44. doi: 10.1016/j.ymthe.2017.10.002
   PubMed Web of Science ®Google Scholar
• Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem. 2003 Feb;278(6):4135–4144. doi: 10.1074/jbc.M205662200
   PubMed Web of Science ®Google Scholar
• Flugel CL, Majzner RG, Krenciute G, et al. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023 Jan;20(1):49–62. doi: 10.1038/s41571-022-00704-3
   PubMed Web of Science ®Google Scholar
• Mahdi J, Dietrich J, Straathof K, et al. Tumor inflammation-associated neurotoxicity. Nat Med. 2023 Apr;29(4):803–810. doi: 10.1038/s41591-023-02276-w
   PubMedGoogle Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol. 2015 Oct;67(2):95–106. doi: 10.1016/j.molimm.2015.01.003
   PubMed Web of Science ®Google Scholar
• Perez P, Hoffman RW, Shaw S, et al. Specific targeting of cytotoxic T cells by anti-T3 linked to anti-target cell antibody. Nature. 1985 Jul;316(6026):354–356. doi: 10.1038/316354a0
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Ko CW, Deisseroth A, et al. FDA approval: Blinatumomab. Clin Cancer Res. 2015 Sep 15;21(18):4035–4039. doi: 10.1158/1078-0432.CCR-15-0612
   PubMed Web of Science ®Google Scholar
• Zhu Z, Presta LG, Zapata G, et al. Remodeling domain interfaces to enhance heterodimer formation: domain interjace remodeling. Protein Sci. 1997 Apr;6(4):781–788. doi: 10.1002/pro.5560060404
   PubMed Web of Science ®Google Scholar
• Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020 Dec;27(1):1. doi: 10.1186/s12929-019-0592-z
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012 Apr;12(4):265–277. doi: 10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Datsi A, Sorg RV. Dendritic cell vaccination of glioblastoma: road to success or dead end. Front Immunol. 2021 Nov 2;12:770390. doi: 10.3389/fimmu.2021.770390
   PubMed Web of Science ®Google Scholar
• Yang T, Shi Y, Liang T, et al. Peptide vaccine against glioblastoma: from bench to bedside. Holist Integr Oncol. 2022 Dec 16;1(1):21. doi: 10.1007/s44178-022-00021-w
   Google Scholar
• Ahluwalia MS, Reardon DA, Abad AP, et al. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2023 Mar 1;41(7):1453–1465. doi: 10.1200/JCO.22.00996
   PubMed Web of Science ®Google Scholar
• Liau LM, Ashkan K, Brem S, et al. Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial. JAMA Oncol. 2023 Jan 1;9(1):112. doi: 10.1001/jamaoncol.2022.5370
   PubMed Web of Science ®Google Scholar
• Liau LM, Ashkan K, Tran DD, et al. First results on survival from a large phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6
   PubMedGoogle Scholar
• Agnihotri S, Zadeh G. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions. Neuro Oncol. 2016 Feb;18(2):160–172. doi: 10.1093/neuonc/nov125
   PubMed Web of Science ®Google Scholar
• Wang X, Prager BC, Wu Q, et al. Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression. Cell Stem Cell. 2018 Apr;22(4):514–528.e5. doi: 10.1016/j.stem.2018.03.011
   PubMed Web of Science ®Google Scholar
• Venkatesh HS, Johung TB, Caretti V, et al. Neuronal activity promotes glioma growth through neuroligin-3 secretion. Cell. 2015 May;161(4):803–816. doi: 10.1016/j.cell.2015.04.012
   PubMed Web of Science ®Google Scholar
• Tirrò E, Massimino M, Romano C, et al. Prognostic and therapeutic roles of the insulin growth factor system in glioblastoma. Front Oncol. 2021 Feb 2;10:612385. doi: 10.3389/fonc.2020.612385
   PubMed Web of Science ®Google Scholar
• Langhans J, Schneele L, Trenkler N, et al. The effects of PI3K-mediated signalling on glioblastoma cell behaviour. Oncogenesis. 2017 Nov 29;6(11):398. doi: 10.1038/s41389-017-0004-8
   PubMedGoogle Scholar
• Zohrabian VM, Forzani B, Chau Z, et al. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res. 2009;29(1):119–123.
   PubMed Web of Science ®Google Scholar